Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Mark Jeffrey Delong Sells 363 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Mark Jeffrey Delong sold 363 shares of the firm’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $28.54, for a total value of $10,360.02. Following the completion of the sale, the insider now directly owns 83,945 shares of the company’s stock, valued at $2,395,790.30. The trade was a 0.43 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Apellis Pharmaceuticals Trading Down 0.1 %

APLS opened at $28.51 on Thursday. The stock’s fifty day moving average is $31.45 and its two-hundred day moving average is $32.30. The company has a market capitalization of $3.55 billion, a P/E ratio of -14.04 and a beta of 0.96. Apellis Pharmaceuticals, Inc. has a 52 week low of $24.34 and a 52 week high of $71.90. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Citigroup lowered their price objective on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. HC Wainwright reiterated a “buy” rating and issued a $57.00 price target on shares of Apellis Pharmaceuticals in a report on Tuesday, January 14th. Wells Fargo & Company reduced their price target on Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 6th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $26.00 price target on shares of Apellis Pharmaceuticals in a report on Wednesday, January 29th. Finally, The Goldman Sachs Group downgraded Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 price target on the stock. in a report on Tuesday, December 17th. Eight analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $46.71.

Institutional Trading of Apellis Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of APLS. EverSource Wealth Advisors LLC boosted its position in Apellis Pharmaceuticals by 2,707.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock valued at $25,000 after acquiring an additional 758 shares in the last quarter. Wolverine Asset Management LLC bought a new stake in Apellis Pharmaceuticals during the 3rd quarter valued at $27,000. True Wealth Design LLC bought a new stake in Apellis Pharmaceuticals during the 3rd quarter valued at $27,000. Signaturefd LLC boosted its position in Apellis Pharmaceuticals by 357.2% during the 4th quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock valued at $37,000 after acquiring an additional 918 shares in the last quarter. Finally, Capital Performance Advisors LLP bought a new stake in Apellis Pharmaceuticals during the 3rd quarter valued at $56,000. Institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).